CZ176494A3 - The use of 3-arylindole and 3-arylindazole derivative for preparing pharmaceutical preparations for treating psychoses - Google Patents

The use of 3-arylindole and 3-arylindazole derivative for preparing pharmaceutical preparations for treating psychoses Download PDF

Info

Publication number: CZ176494A3
Authority: CZ; Czechia
Prior art keywords: arylindole; alkyl; arylindazole; psychoses; compounds
Prior art date: 1992-01-23

Application number

CZ941764A

Other languages

Czech (cs)

English (en)

Inventor

Kim Andersen

Torben Skarsfeldt

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-01-23

Filing date

1993-01-22

Publication date

1995-04-12

1993-01-22 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

1995-04-12 Publication of CZ176494A3 publication Critical patent/CZ176494A3/cs

Links

208000028017 Psychotic disease Diseases 0.000 title claims abstract description 15
239000000825 pharmaceutical preparation Substances 0.000 title 1
238000011282 treatment Methods 0.000 claims abstract description 13
125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 12
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
239000001257 hydrogen Substances 0.000 claims abstract description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 6
150000001875 compounds Chemical class 0.000 claims description 31
150000003839 salts Chemical class 0.000 claims description 16
239000002253 acid Substances 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
-1 3- (2-propyl) imidazolidin-2-one-1-yl Chemical group 0.000 claims description 5
239000002243 precursor Substances 0.000 claims description 5
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 2
AGUCBOFUNNXJHC-UHFFFAOYSA-N 1-[2-[4-[3-(4-fluorophenyl)-5-(trifluoromethyl)indol-1-yl]-3,6-dihydro-2h-pyridin-1-yl]ethyl]imidazolidin-2-one Chemical compound C1=CC(F)=CC=C1C(C1=CC(=CC=C11)C(F)(F)F)=CN1C(CC1)=CCN1CCN1C(=O)NCC1 AGUCBOFUNNXJHC-UHFFFAOYSA-N 0.000 claims 1
125000000217 alkyl group Chemical group 0.000 abstract description 21
125000000753 cycloalkyl group Chemical group 0.000 abstract description 9
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract description 9
125000003342 alkenyl group Chemical group 0.000 abstract description 8
210000004556 brain Anatomy 0.000 abstract description 8
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 8
125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract description 7
229910052736 halogen Inorganic materials 0.000 abstract description 7
150000002367 halogens Chemical class 0.000 abstract description 7
229910052757 nitrogen Inorganic materials 0.000 abstract description 7
229910052760 oxygen Inorganic materials 0.000 abstract description 7
229910052717 sulfur Inorganic materials 0.000 abstract description 7
210000002569 neuron Anatomy 0.000 abstract description 6
125000003545 alkoxy group Chemical group 0.000 abstract description 5
125000004093 cyano group Chemical group *C#N 0.000 abstract description 5
229960003638 dopamine Drugs 0.000 abstract description 4
125000003282 alkyl amino group Chemical group 0.000 abstract description 3
125000004390 alkyl sulfonyl group Chemical group 0.000 abstract description 3
125000004414 alkyl thio group Chemical group 0.000 abstract description 3
125000004663 dialkyl amino group Chemical group 0.000 abstract description 3
125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 abstract description 3
125000001424 substituent group Chemical group 0.000 abstract description 2
210000004515 ventral tegmental area Anatomy 0.000 abstract description 2
238000010304 firing Methods 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
230000000694 effects Effects 0.000 description 26
241000700159 Rattus Species 0.000 description 15
230000005764 inhibitory process Effects 0.000 description 15
239000000126 substance Substances 0.000 description 12
238000001727 in vivo Methods 0.000 description 10
238000012360 testing method Methods 0.000 description 10
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 8
230000002401 inhibitory effect Effects 0.000 description 8
201000000980 schizophrenia Diseases 0.000 description 8
230000000561 anti-psychotic effect Effects 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
238000003556 assay Methods 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 5
229960004170 clozapine Drugs 0.000 description 5
229940125904 compound 1 Drugs 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000007794 irritation Effects 0.000 description 5
125000004433 nitrogen atom Chemical group N* 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000006378 damage Effects 0.000 description 4
229960003878 haloperidol Drugs 0.000 description 4
208000014674 injury Diseases 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000001537 neural effect Effects 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
239000000600 sorbitol Substances 0.000 description 4
125000004434 sulfur atom Chemical group 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
125000005843 halogen group Chemical group 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
230000000926 neurological effect Effects 0.000 description 3
DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 3
229960004851 pergolide Drugs 0.000 description 3
YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
XRXDAJYKGWNHTQ-UHFFFAOYSA-N quipazine Chemical compound C1CNCCN1C1=CC=C(C=CC=C2)C2=N1 XRXDAJYKGWNHTQ-UHFFFAOYSA-N 0.000 description 3
229950002315 quipazine Drugs 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 description 2
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 2
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000009132 Catalepsy Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010026749 Mania Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
206010047853 Waxy flexibility Diseases 0.000 description 2
239000000556 agonist Substances 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
239000003693 atypical antipsychotic agent Substances 0.000 description 2
230000006399 behavior Effects 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 2
229940125782 compound 2 Drugs 0.000 description 2
229940126214 compound 3 Drugs 0.000 description 2
230000003291 dopaminomimetic effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012458 free base Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
125000004430 oxygen atom Chemical group O* 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 2
230000003860 sleep quality Effects 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
AOVJKFZMDSJQDY-UHFFFAOYSA-N 1-[2-[4-[3-(4-fluorophenyl)-5-methylindol-1-yl]piperidin-1-yl]ethyl]-3-propan-2-ylimidazolidin-2-one Chemical compound O=C1N(C(C)C)CCN1CCN1CCC(N2C3=CC=C(C)C=C3C(C=3C=CC(F)=CC=3)=C2)CC1 AOVJKFZMDSJQDY-UHFFFAOYSA-N 0.000 description 1
LZSPHUKWGNMGSE-UHFFFAOYSA-N 1-[2-[4-[3-(4-fluorophenyl)-5-methylindol-1-yl]piperidin-1-yl]ethyl]imidazolidin-2-one Chemical compound C12=CC(C)=CC=C2N(C2CCN(CCN3C(NCC3)=O)CC2)C=C1C1=CC=C(F)C=C1 LZSPHUKWGNMGSE-UHFFFAOYSA-N 0.000 description 1
125000006017 1-propenyl group Chemical group 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
108091005479 5-HT2 receptors Proteins 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
201000010000 Agranulocytosis Diseases 0.000 description 1
206010001540 Akathisia Diseases 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
244000223760 Cinnamomum zeylanicum Species 0.000 description 1
241001573498 Compacta Species 0.000 description 1
208000014094 Dystonic disease Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010028347 Muscle twitching Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000027089 Parkinsonian disease Diseases 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
206010042008 Stereotypy Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
125000005137 alkenylsulfonyl group Chemical group 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
229940025084 amphetamine Drugs 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000001090 anti-dopaminergic effect Effects 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
229960004046 apomorphine Drugs 0.000 description 1
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
238000004820 blood count Methods 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
235000017803 cinnamon Nutrition 0.000 description 1
229960001184 clopenthixol Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
208000010118 dystonia Diseases 0.000 description 1
230000002870 effect on schizophrenia Effects 0.000 description 1
125000006125 ethylsulfonyl group Chemical group 0.000 description 1
239000012467 final product Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229960002419 flupentixol Drugs 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229960005417 ketanserin Drugs 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000000034 method Methods 0.000 description 1
229960001344 methylphenidate Drugs 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
230000002474 noradrenergic effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
239000003087 receptor blocking agent Substances 0.000 description 1
230000000698 schizophrenic effect Effects 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000000862 serotonergic effect Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical group C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
229960000652 sertindole Drugs 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
230000007958 sleep Effects 0.000 description 1
229950001675 spiperone Drugs 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
210000003523 substantia nigra Anatomy 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000001519 thymoleptic effect Effects 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
238000005303 weighing Methods 0.000 description 1
WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

CZ941764A 1992-01-23 1993-01-22 The use of 3-arylindole and 3-arylindazole derivative for preparing pharmaceutical preparations for treating psychoses CZ176494A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK9284A DK8492D0 (da)	1992-01-23	1992-01-23	Behandling af psykoser

Publications (1)

Publication Number	Publication Date
CZ176494A3 true CZ176494A3 (en)	1995-04-12

Family

ID=8089556

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ941764A CZ176494A3 (en)	1992-01-23	1993-01-22	The use of 3-arylindole and 3-arylindazole derivative for preparing pharmaceutical preparations for treating psychoses

Country Status (11)

Country	Link
EP (1)	EP0621781A1 (da)
JP (1)	JPH07503240A (da)
AU (1)	AU670063B2 (da)
CA (1)	CA2128699A1 (da)
CZ (1)	CZ176494A3 (da)
DK (1)	DK8492D0 (da)
NO (1)	NO942686L (da)
RU (1)	RU94035658A (da)
SK (1)	SK86394A3 (da)
WO (1)	WO1993014758A1 (da)
ZA (1)	ZA93491B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK206591D0 (da) *	1991-12-23	1991-12-23	Lundbeck & Co As H	Behandling af psykoser
ES2226129T3 (es) *	1997-05-30	2005-03-16	Banyu Pharmaceutical Co., Ltd.	Derivados de 2-0x0imidazol.
US7781478B2 (en)	2004-07-14	2010-08-24	Ptc Therapeutics, Inc.	Methods for treating hepatitis C

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE58370B1 (en) *	1985-04-10	1993-09-08	Lundbeck & Co As H	Indole derivatives
GB8908085D0 (en) *	1989-04-11	1989-05-24	Lundbeck & Co As H	New therapeutic use
DK181190D0 (da) *	1990-07-30	1990-07-30	Lundbeck & Co As H	3-aryl-indol- eller 3-aryl-indazolderivater

1992
- 1992-01-23 DK DK9284A patent/DK8492D0/da not_active Application Discontinuation
1993
- 1993-01-22 AU AU34494/93A patent/AU670063B2/en not_active Ceased
- 1993-01-22 ZA ZA93491A patent/ZA93491B/xx unknown
- 1993-01-22 WO PCT/DK1993/000021 patent/WO1993014758A1/en not_active Ceased
- 1993-01-22 JP JP5512865A patent/JPH07503240A/ja active Pending
- 1993-01-22 EP EP93903188A patent/EP0621781A1/en not_active Withdrawn
- 1993-01-22 SK SK863-94A patent/SK86394A3/sk unknown
- 1993-01-22 CA CA002128699A patent/CA2128699A1/en not_active Abandoned
- 1993-01-22 CZ CZ941764A patent/CZ176494A3/cs unknown
1994
- 1994-07-18 NO NO942686A patent/NO942686L/no unknown
- 1994-07-22 RU RU94035658/14A patent/RU94035658A/ru unknown

Also Published As

Publication number	Publication date
CA2128699A1 (en)	1993-08-05
ZA93491B (en)	1993-08-23
NO942686D0 (no)	1994-07-18
RU94035658A (ru)	1996-06-20
SK86394A3 (en)	1995-04-12
JPH07503240A (ja)	1995-04-06
AU670063B2 (en)	1996-07-04
DK8492D0 (da)	1992-01-23
AU3449493A (en)	1993-09-01
WO1993014758A1 (en)	1993-08-05
NO942686L (no)	1994-07-18
EP0621781A1 (en)	1994-11-02

Publication	Publication Date	Title
CA2014208C (en)	1996-03-19	Selective blocking of spontaneously-active dopamine neurones in ventral tegmental area
US5238945A (en)	1993-08-24	Method of treating psychoses
CZ93097A3 (en)	1997-09-17	5-ht1f mediated inhibition of neurogenic meningeal extravasate
CZ293478B6 (cs)	2004-05-12	Farmaceutický prostředek
EP0533824A1 (en)	1993-03-31	SUBSTITUTED PIPERIDYLE INDOLES.
JP4740152B2 (ja)	2011-08-03	末梢性５−ｈｔ受容体の修飾因子
KR102016120B1 (ko)	2019-10-21	순수한 5-ht6 수용체 길항제, 아세틸콜린에스테라제 저해제 및 nmda 수용체 길항제의 3중 조합물
CZ295776B6 (cs)	2005-11-16	Opticky čistý (+)-norcisaprid pro léčení gastroesofageálního refluxu
HUP0104019A2 (en)	2002-06-29	Prophylactic use of n-methyl-d-aspartate (nmda) antagonists
CZ176494A3 (en)	1995-04-12	The use of 3-arylindole and 3-arylindazole derivative for preparing pharmaceutical preparations for treating psychoses
KR102023748B1 (ko)	2019-09-20	순수한 5-ht6 수용체 길항제 및 nmda 수용체 길항제의 조합물
CA2105385C (en)	2000-08-15	Treatment of cognitive disorders
KR20070043965A (ko)	2007-04-26	Ｎｒ2ｂ 수용체 길항물질인 키뉴렌산 아미드 유도체
AU668537B2 (en)	1996-05-09	Use of arylindole derivatives for the treatment of psychoses
GB2362826A (en)	2001-12-05	A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
JP2024156953A (ja)	2024-11-06	認知症患者における行動・心理症状を治療するための方法
HK1002825B (en)	1998-09-18	Use of sertindole for the treatment of schizophrenia